Loading...
Market
In which quarter of 2025 will AbbVie complete Aliada's integration?
2
Resolution / Starting Odds
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%
AbbVie's official press releases or financial reports
Story
AbbVie to Acquire J&J-Backed Aliada Therapeutics for $1.4 Billion in Alzheimer's Focus
Oct 28, 2024, 01:52 PM
AbbVie Inc. announced on Monday that it will acquire Aliada Therapeutics, a privately held therapy developer, for $1.4 billion in cash. The acquisition is aimed at strengthening AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. Aliada Therapeutics, a J&J-backed company, is known for its lead compound ALIA-1758 and its novel blood-brain barrier technology, which are expected to enhance AbbVie's capabilities in developing treatments for neurodegenerative diseases. This deal, involving a Phase 1 biotech, marks AbbVie's third acquisition of the year and underscores its commitment to expanding its research and development in the central nervous system (CNS) domain.
View original story
Similar markets
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Significant growth (>10%) • 25%
Moderate growth (5-10%) • 25%
Minimal growth (<5%) • 25%
No growth or decline • 25%
Less than 3% • 25%
3% to 4% • 25%
4% to 5% • 25%
More than 5% • 25%
Skyrizi • 25%
Rinvoq • 25%
Humira • 25%
Other • 25%